Extracorporeal Therapy and Therapeutic Drug Monitoring
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: ICU Patients With ECMO And-or RRT and With Gram Negative Infections Susceptible to BL-BLIs. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pharmacokinetics/Pharmacodynamics and Therapeutic Drug Monitoring of Novel β-lactams and β-lactamase Inhibitors in Critically Ill Patients Undergoing Extracorporeal Therapy
Overview
The aim of this study is to comparatively evaluate serum concentrations of continuously applied antibiotics in ICU patients, with and without ECMO/RRT support.
Detailed description
Among all patients being treated with new generation antibiotics (beta.lactams and beta-lactamase inhibitors), we will take into consideration the results of those admitted to intensive care units.
Effective antimicrobial treatment is critical to reduce their mortality associated with bacterial sepsis. They often also require extracorporeal supports, such as renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO), for their survival. However, few studies, limited only to some drugs, report the importance of therapeutic drug monitoring for adequate dose adjustment in these particular conditions of extracoporeal support.
The risk of reaching sub therapeutic or toxic levels is quite high, due to possible very significant variations in the pharmacokinetics of the drugs because of their interaction with the various components of the ECMO and RRT devices, the characteristics of the drug itself and the pathophysiological changes of the patients on ECMO and/or RRT.
Primary aim is to evaluate whether the standard prescriptions of beta lactams/beta lactamase inhibitors (BL/BLIs) are adequate to achieve the optimal PK/PD target also for ECMO and RRT (or combined) patients admitted to intensive care unit.
Secondary aims include to evaluate:
* the occurrence of sub-therapeutic and/or toxic drugs levels * the proportion of patients with insufficient drugs levels in different subgroups (i.e., absence of extracorporeal therapy vs. ECMO; absence of extracorporeal therapy vs. RRT, absence of extracorporeal therapy vs ECMO and RRT) - the proportion of patients with toxic or sub-therapeutic drugs levels in the same subgroups; * the proportion, when possible, of drugs level before and during the extracorporeal therapy, for the same patient; * the occurrence of drug resistance by pathogens and their mechanism
Primary outcome measures
- Primary aim [Time frame: up to 24 months]
Secondary outcome measures (5)
- occurrence of sub-therapeutic and/or toxic drugs levels [Time frame: up to 24 months]
- proportion of patients with insufficient drugs levels in different subgroups [Time frame: up to 24 months]
- proportion of patients with toxic or sub-therapeutic drugs levels in the same subgroups [Time frame: up to 24 months]
- proportion, when possible, of drugs level before and during the extracorporeal therapy, for the same patient [Time frame: up to 24 months]
- occurrence of drug resistance by pathogens and their mechanism [Time frame: up to 24 months]
Eligibility criteria
Inclusion criteria
- adult patients (age 18y or older)
- admitted to ICU
- supported or not-supported with extracorporeal membrane oxygenation (ECMO) and/or renal replacement therapy (RRT)
- affected by gram-negative bacterial infections susceptible to the novel antibiotics.
Exclusion criteria
- Pediatric age (<18y)
- allergies to pharmaceutical and/or inactive drug ingredients (excipients)
- life expectancy less than 1 month
- body mass index (BMI) >45 kg/m2
- pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Fondazione IRCCS Policlinico San Matteo — Pavia
Identifiers
NCT: NCT07287813 · BL/BLIs in ICU - 2024